Is There Life for This Struggling Health-Care Business?

Before you go, we thought you'd like these...
Before you go close icon

Panasonic's not the first company you may think of in the health-care field, but this Japanese electronics maker's a player in blood glucose monitors and other fields. With Panasonic's sales under fire across the board, however, this company's looking to sell off its health-care business to refocus on its core segments. Toshiba reportedly has expressed interest in a buy, and private equity-firms are also in the hunt to get on board with Asia's health-care rise.

Buying into the Asian health-care scene isn't anything new. Stryker made waves earlier this year by purchasing Chinese spine and trauma firm Trauson for $764 million, and with China's health-care industry still in a state of transition, this is a potent grow opportunity for device firms. But is Panasonic's business worth all that much to buyers? Motley Fool contributor Dan Carroll and health-care analyst Max Macaluso discuss what you need to know in the following video.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

The article Is There Life for This Struggling Health-Care Business? originally appeared on

Fool contributor Dan Carroll, Max Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

People are Reading